Featured News
Accelerated Decision-making with Scalable Spatial Pathology
Make Spatial Pathology Reproducible at Scale, So Your Program Moves Faster
If you lead a translational program, you need answers you can trust, and you need them on a timeline your study can support. That’s why the partnership between Akoya (now part of Quanterix) and Charles River was designed from the ground up to give your team a unified experience: Akoya provides spatial imaging technology and performance standards; Charles River delivers the operational depth, regulatory alignment, and scientific continuity to apply those standards consistently across programs.
This eGuide is your essential resource for understanding the advantages of what today’s digital pathology solutions can provide in your race to market.
Read Now
One network, one standard
High plex spatial pathology only works at scale when imaging platforms, staining methods, analysis workflows, and QC expectations are aligned. Through the Akoya–Charles River partnership, you operate inside a single, integrated framework where technology and execution are intentionally matched.
What Akoya brings
Akoya’s spatial imaging platforms—and their Qualified CRO Service Provider Network—establish a unified bar for staining, imaging, and analysis proficiency. This network allows sponsors to use harmonized methods across vetted providers, minimizing site-to-site drift and keeping multisite studies on track.
With Akoya joining Quanterix in July 2025, tissue-based spatial imaging now sits alongside a broader portfolio of translational assays under a single organization. This consolidation simplifies planning for sponsors who need multi modality biomarker strategies.
Charles River Offerings
Charles River turns those scientific standards into operational reality. We implement Akoya’s platform within GLP-aligned workflows—including multiplex staining using Leica and Roche automated staining instruments, RNA scope technology for in situ (hybridization), and Visiopharm for quantitative image analysis—to ensure your assays run consistently from small pilot work to large translational and clinical research programs.
Where Akoya defines the imaging and analysis expectations, Charles River provides:
- a single CRO partner spanning discovery → safety assessment → clinical research,
- integrated study design and execution,
- and expert data review supported by pathologists, tissue biomarker experts, and translational science teams.
Instead of stitching together multiple vendors, you gain one coordinated engine capable of applying Akoya’s standards at every study stage.
High plex spatial pathology only delivers value at scale when scientific standards and operational execution are perfectly aligned. Our role is to make sure those standards perform the same way—study after study—so sponsors can trust their decisions”
Frédéric Gervais, Associate Director, Pathology, Evreux, France
In July 2025, Akoya joined Quanterix, bringing tissue-based spatial imaging together with a broader biomarker portfolio under one company. This alignment simplifies how sponsors plan large, multi-modality programs, while Charles River provides the delivery engine to run them efficiently, compliantly, and at scale.
Together, Akoya and Charles River provide: One technological standard for high plex spatial profiling:
- One operational model that extends from discovery to safety assessment and into the clinic
- One unified workflow that reduces variability, accelerates reviews, and shortens decision timelines
The result is a fully integrated experience: Akoya sets the scientific standard; Charles River ensures it performs the same way, every time, in the context of your study goals.